Holen Sie sich die Stockscreener-App
2.22
2.30%
0.05
Handel nachbörslich:
2.15
-0.07
-3.15%
Schlusskurs vom Vortag:
$2.17
Offen:
$2.18
24-Stunden-Volumen:
1.21M
Relative Volume:
2.35
Marktkapitalisierung:
$159.46M
Einnahmen:
$31.25M
Nettoeinkommen (Verlust:
$-88.48M
KGV:
-1.4323
EPS:
-1.55
Netto-Cashflow:
$-79.63M
1W Leistung:
+29.82%
1M Leistung:
+86.55%
6M Leistung:
+63.24%
1J Leistung:
-58.66%
1-Tages-Spanne:
$2.15
$2.31
1-Wochen-Bereich:
$1.65
$2.31
52-Wochen-Spanne:
$0.5902
$5.705
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 19.7% in October - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Cross Above 50-Day Moving AverageWhat's Next? - MarketBeat
Contrasting Star Equity (NASDAQ:STRR) and Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc - Yahoo Finance
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLC - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $23.50 Consensus Target Price from Analysts - MarketBeat
Stonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MSN
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
Accenture (NYSE:ACN) PT Raised to $365.00 - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World
Investing in Astrazeneca plc ADR (AZN) Is Getting More Attractive - Knox Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
Metric Deep Dive: Understanding Accenture plc (ACN) Through its Ratios - The Dwinnex
American Century Companies Inc. Boosts Stock Position in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial - Clinical Trials Arena
Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Neutral” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily
Accel Entertainment CEO sells shares worth over $49,000 By Investing.com - Investing.com UK
Arch Capital Group (ACGL) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright - MarketBeat
Meeder Advisory Services Inc. Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - Defense World
William Blair Investment Management LLC Sells 17,390 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Arch Capital Group (NASDAQ:ACGL) Sets New 1-Year High at $114.69 - MarketBeat
(ACEL) Long Term Investment Analysis - Stock Traders Daily
Analyzing Axcelis Technologies Inc (ACLS) After Recent Trading Activity - Knox Daily
Quest Partners LLC Cuts Stake in Accel Entertainment, Inc. (NYSE:ACEL) - Defense World
Financial Metrics Exploration: Understanding Acrivon Therapeutics Inc (ACRV) Through Ratios - The Dwinnex
Market Watch: Aclarion Inc (ACON)’s Noteworthy Drop, Closing at 0.18 - The Dwinnex
Citi lifts Accenture stock price target on growth prospects - Investing.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Analysts - MarketBeat
Aclaris Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis - Yahoo Finance
Quest Partners LLC Grows Position in Cardlytics, Inc. (NASDAQ:CDLX) - Defense World
Arch Capital Group (ACGL) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Accenture (ACN) Rises Higher Than Market: Key Facts - Yahoo Finance
AstraZeneca PLC ADR rises Monday, outperforms market - MarketWatch
Market Momentum: Astrazeneca plc ADR (AZN) Registers a -0.87 Decrease, Closing at 78.27 - The Dwinnex
Acrivon Therapeutics: Promising Trial Results and FDA Clearance - TipRanks
Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg - TipRanks
ICA Group Wealth Management LLC Decreases Stock Position in Accenture plc (NYSE:ACN) - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Lifted to Strong-Buy at StockNews.com - Defense World
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aclaris Therapeutics Inc-Aktie (ACRS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
| Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
| Leonard Braden Michael | 10% Owner |
Jul 05 '24 |
Buy |
1.15 |
123,017 |
141,334 |
13,447,969 |
| Leonard Braden Michael | 10% Owner |
Jul 02 '24 |
Buy |
1.14 |
86,092 |
98,489 |
13,181,664 |
3.48%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):